CQN-PHENOM
8.10.2021 04:02:09 CEST | Business Wire | Press release
Fourth paragraph, first sentence of release dated October 6, 2021, should read: As the vice president and general manager for Phenom in Central Europe, Gerstner will be responsible for strengthening existing and new customer relationships in Central Europe, including Germany, Austria, Switzerland, France and BENELUX (instead of in Germany, Austria and Switzerland).
The updated release reads:
PHENOM HIRES SENIOR LEADERS TO OVERSEE RAPID GROWTH IN EUROPE
Thomas Gerstner and Andy Joeres bring decades of experience scaling SaaS enterprises in EMEA
Phenom , the global leader in Talent Experience Management (TXM), today announced the hiring of two executives to drive the company’s surging global growth. Thomas Gerstner will lead Phenom’s business in Central Europe, and Andy Joeres will oversee initiatives in the United Kingdom and Ireland, Northern Europe, Middle East and Africa. The positions were created to continue building momentum in EMEA, where there has been an exploding demand for talent experience, AI and automation from HR teams.
Following numerous acquisitions and the addition of many enterprise customers in EMEA, Phenom’s headcount in Europe has quickly exceeded 100 employees. With operations in the United Kingdom, Ireland, Germany, Netherlands, France, Italy, Spain, Sweden, and Switzerland, Phenom expects to continue aggressively recruiting into 2022 across customer success, sales, account management, marketing, engineering, product and more.
“The need for AI-powered talent experiences is universal, and the interest in Phenom’s platform originating from EMEA is increasing every day,” said Mahe Bayireddi, co-founder and CEO of Phenom. “We’re thrilled that Andy and Thomas are joining our team. They carry proven track records of success meeting ambitious business objectives in many different markets around the world, and we expect their leadership will inspire our talented overseas team to bring amazing talent experiences to global enterprises.”
As the vice president and general manager for Phenom in Central Europe, Gerstner will be responsible for strengthening existing and new customer relationships in Central Europe, including Germany, Austria, Switzerland, France and BENELUX. In his last role, he was the EMEA president of Pathlock — defining, implementing, and executing growth strategy across all channels. For 14 years, Gerstner also held various senior executive roles at SAP, including senior vice president for the SuccessFactors business in the Middle and Eastern European region and managing director in Asia.
“Phenom is already turning heads in Central Europe, and it’s incredible to now be part of this special journey,” said Gerstner. “Organisations that have invested in AI-powered talent experiences are miles ahead of their competitors. Already in Central Europe, Phenom’s sophisticated platform is making a huge difference, helping organizations transform the way they acquire, develop and retain talent.”
Joeres will serve as Phenom’s vice president of sales for EMEA, where he will focus on bringing new business to the company. Joeres has managed the launch of hyper-growth initiatives for companies like Celonis and Snow, where he spearheaded triple-digit, year-over-year growth and exponentially scaled personnel from small teams to large units with deep impact across the enterprise.
“My passion has always been designing go-to-market strategies and then executing them for companies that have a clear, profound vision,” said Joeres. “HR teams are realizing that intelligent experiences are the present and future of hiring and retaining the best talent — and the Phenom TXM platform is the solution. AI and automation are now requirements for scaling those experiences. I look forward to championing Phenom’s platform to help organisations reduce cost and time to hire, while increasing employee retention.”
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalizes and automates the talent journey for candidates, recruiters, employees and management with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates and employees find the right job, recruiters identify and engage the right talent, and management optimizes HR strategy, process and spend. Phenom was ranked among the fastest-growing technology companies in the 2020 Deloitte Technology Fast 500, and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com . Connect with Phenom on LinkedIn , Twitter , Facebook , YouTube and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005383/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom